Improving the Detection of Hypertension and its Control
Improving the Detection of Hypertension and its Control
批准号:
10573169
负责人:
Kristi Reynolds
金额:
$208.83万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-02-15 至 2026-01-31
关键词:
AdultAgeAlbuminsAmbulatory Blood Pressure MonitoringAntihypertensive AgentsAsianBlack raceBlood PressureBlood Pressure MonitorsCardiovascular DiseasesCreatinineDataDetectionDevicesDiagnosisDiastolic blood pressureEchocardiographyElderlyEnrollmentEthnic OriginEthnic PopulationGuidelinesHealthHispanicHome Blood Pressure MonitoringHourHypertensionIndividualLeft Ventricular MassLos AngelesMeasurementMeasuresMedicalMethodsMinorityNew YorkNot Hispanic or LatinoOffice VisitsOrganOutcomeParticipantPharmaceutical PreparationsPublic HealthRaceRandomizedRecommendationReference StandardsReportingReproducibilityResearch DesignRisk FactorsSamplingSiteTestingVisitWomanage differenceage groupawakebiomarker validationblood pressure controldisability-adjusted life yearshypertension controlhypertensiveimprovedindexingmodifiable riskprimary outcomescreeningsecondary outcomesexurinaryyears of life lostyoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Blood pressure (BP) measured in the office is used to diagnose hypertension and guide BP management for
adults taking antihypertensive medication. Guidelines recommend measuring BP outside of the office using
ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) to confirm office BP, averaged across
multiple visits. The evidence supporting this recommendation is weak since most prior studies compared BP
on ABPM or HBPM against office BP measured at a single visit. Guidelines also recommend that ABPM be
performed over a 24-hour period and HBPM be based on 2 measurements in the morning (AM) and 2
measurements in the evening (PM) for 7 days. Many guidelines endorse ABPM as the reference standard for
out-of-office BP monitoring, but there are few data comparing ABPM to HBPM conducted for 7 days. We
recently completed a study of 400 adults that compared BP measured during 3 office visits, on ABPM, and
HBPM, each conducted following guideline-recommended approaches. The study found (1) BP on HBPM was
associated with left ventricular mass index (LVMI), a marker of target end-organ damage, independent of office
BP and BP on ABPM, (2) office BP and BP on ABPM were not associated with LVMI, independent of BP on
HBPM, (3) HBPM was more reliable (i.e. reproducible) than ABPM and office BP, and (4) office BP was more
reliable than ABPM. These results suggest a new paradigm that HBPM is superior to ABPM and office
BP, and ABPM is not needed when office BP and HBPM are both performed. However, no one in this
study was taking antihypertensive medication, few older adults were enrolled, and a minority had high office
BP. These findings need to be tested in a larger study with broader generalizability. We propose to enroll 1,696
adults in New York, NY, Birmingham, AL, and Los Angeles, CA with screening systolic/diastolic BP <160/100
mm Hg; 50% of whom will be taking antihypertensive medication. The sample will be diverse based on age
(33% in each age group: 18-39, 40-59, and ≥60 years), sex (50% women), race/ethnicity (≥25% non-Hispanic
white, ≥25% non-Hispanic Black, ≥25% Hispanic, and ≥10% Asian), and office BP level (50% with office BP
≥130/80 mm Hg). Office BP will be measured at 3 visits. ABPM will be performed over two 24-hour periods and
HBPM will be performed with 2 AM and 2 PM measurements per day over two 7-day periods. Two markers of
target end-organ damage – LVMI on echocardiogram and albumin-to-creatinine ratio – will be assessed. We
will determine whether BP on HBPM is more strongly associated with target end-organ damage than office BP
and awake BP on ABPM (Primary Aim 1). We will determine if HBPM is more reliable than office BP and
awake BP on ABPM (Primary Aim 2). We will also determine whether the findings are consistent using asleep
BP and 24-hour BP instead of awake BP, and investigate potential differences among age, sex, and
race/ethnicity subgroups (Secondary Aims). The study will determine the best approach to measure BP for
diagnosing and managing hypertension, which has the potential to improve the health of millions of US adults.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Assessing the Burden of Diabetes by Type in Children, Adolescents and Young Adults (DiCAYA) - Component B (18 to < 45 yrs)
-
批准号:10636654
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2020
-
负责人:Kristi Reynolds
-
依托单位:
Assessing the Burden of Diabetes by Type in Children, Adolescents and Young Adults (DiCAYA) - Component B (18 to < 45 yrs)
-
批准号:10223096
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2020
-
负责人:Kristi Reynolds
-
依托单位:
Assessing the Burden of Diabetes by Type in Children, Adolescents and Young Adults (DiCAYA) - Component B (18 to < 45 yrs)
-
批准号:10414406
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2020
-
负责人:Kristi Reynolds
-
依托单位:
Ambulatory blood pressure and falls in older treated patients with hypertension
-
批准号:10163696
-
项目类别:
-
资助金额:$74.99万
-
财政年份:2018
-
负责人:Kristi Reynolds
-
依托单位:
Population-based diabetes in youth registry. SEARCH For Diabetes in Youth, Phase 4, California Site
-
批准号:9753808
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2015
-
负责人:Kristi Reynolds
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: